Trial reportJournal of general internal medicine2012
The average lifespan of patients discharged from hospital with heart failure.
Trial report in Journal of general internal medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 52 citations in OpenAlex.
- Virtual healthcare solutions in heart failure: a literature review.Frontiers in cardiovascular medicine · 2023Review
- Financial burden of heart failure in Malaysia: A perspective from the public healthcare system.PloS one · 2023Article
- Adverse Events After Initiating Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy in Individuals with Heart Failure and Multimorbidity.The American journal of medicine · 2022Article
- Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF.European journal of heart failure · 2021Article
- Kidney Function and Outcomes in Patients Hospitalized With Heart Failure.Journal of the American College of Cardiology · 2021Article
- Physician Perspectives on the Diagnosis and Management of Heart Failure With Preserved Ejection Fraction.CJC open · 2021Article
- Noncardiac-Related Morbidity, Mobility Limitation, and Outcomes in Older Adults With Heart Failure.The journals of gerontology. Series A, Biological sciences and medical sciences · 2020Article
- Progressive Reinvention or Destination Lost? Half a Century of Cardiovascular Tissue Engineering.Frontiers in cardiovascular medicine · 2020Review
- Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China.Frontiers in pharmacology · 2020Article
- Physiologic expansion of human heart-derived cells enhances therapeutic repair of injured myocardium.Stem cell research & therapy · 2019Article
- End-of-life discussions in advanced heart failure.Canadian family physician Medecin de famille canadien · 2019Article
- Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States.PharmacoEconomics · 2019Article
- Multimorbidity Burden and Adverse Outcomes in a Community-Based Cohort of Adults with Heart Failure.Journal of the American Geriatrics Society · 2018Article
- Treatment Effectiveness in Heart Failure with Comorbidity: Lung Disease and Kidney Disease.Journal of the American Geriatrics Society · 2017Article
- Caregiver determinants of patient clinical event risk in heart failure.European journal of cardiovascular nursing · 2017Article
- The cost-utility of point-of-care troponin testing to diagnose acute coronary syndrome in primary care.BMC cardiovascular disorders · 2017Article
- Long-term mortality in older patients discharged after acute decompensated heart failure: a prospective cohort study.BMC geriatrics · 2017Article
- Electrical effects of stem cell transplantation for ischaemic cardiomyopathy: friend or foe?The Journal of physiology · 2016Review
- Economic evaluation of a hospital-initiated intervention for smokers with chronic disease, in Ontario, Canada.Tobacco control · 2015Article
- A qualitative study of the current state of heart failure community care in Canada: what can we learn for the future?BMC health services research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundThere are no life-tables quantifying the average life-spans of post-hospitalized heart failure populations across various strata of risk.
objectiveTo quantify the life-expectancies (i.e., average life-spans) of heart failure patients at the time of hospital discharge according to age, gender, predictive 30-day mortality heart failure risk index, and comorbidity burden.
designPopulation-based retrospective cohort study.
settingOntario, Canada. PATIENTS: 7,865 heart failure patients discharged from Ontario hospitals between 1999 and 2000. MEASUREMENTS: Data were obtained from the Enhanced Feedback for Effective Cardiac Treatment EFFECT provincial quality improvement initiative. All patients were linked to administrative data, and tracked longitudinally until March 31, 2010. Detailed clinical variables were obtained from medical chart abstraction, and death data were obtained from vital statistics. Average life-spans were calculated using Cox Proportion Hazards models in conjunction with the Declining Exponential Approximation of Life Expectancy (D.E.A.L.E) method to extrapolate life-expectancy, adjusting for age, gender, predicted 30-day mortality, left ventricular function and comorbidity, and was reported according to key prognostic risk-strata.
resultsThe average life-span of the cohort was 5.5 years (STD +/- 10.0) ranging from 19.5 years for low-risk women of less than 50 years old to 2.9 years for high-risk octogenarian males. Average life-spans were lower by 0.13 years among patients with impaired as compared with preserved left ventricular function, and by approximately one year among patients with three or more as compared with no concomitant comorbidities. In total, 17.4 % and 27 % of patients had died within 6 months and 1 year respectively, despite having predicted life-spans exceeding one-year. LIMITATIONS: Data regarding changes in patient clinical status over time were unavailable.
conclusionsThe development of risk-adjusted life-tables for heart failure populations is feasible and mirrored those with advanced malignant diseases. Average life span varied widely across clinical risk strata, and may be less accurate among those at or near their end of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.